“Because Arthrex issued after the Board’s final-written decisions and after New Vision sought Board rehearing, New Vision has not waived its Arthrex challenge by raising it for the first time in its opening brief before this Court . . . Thus, we vacate and remand for further proceedings consistent with Arthrex, and we need not reach any other issue presented in this case.”